3-氯苯硫酰胺 | 2548-79-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯苯硫酰胺
• 中文别名: 间氯硫代苯甲酰胺；3-氯硫代苯甲酰胺
• 英文名称: 3-chlorothiobenzamide
• 英文别名: m-Chlor-thiobenzamid；3-Chlor-thiobenzamid；3-chlorobenzothioamide；3-chlorobenzenecarbothioamide
• CAS: 2548-79-0
• 化学式: C₇H₆ClNS
• mdl: MFCD00276993
• 分子量: 171.65
• InChiKey: OQEBJXXIPHYYEG-UHFFFAOYSA-N

物化性质

• 熔点：
  110 °C
• 沸点：
  289.5±42.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下保持稳定，应避免与氧化物直接接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 危险品运输编号：
  UN2811
• 海关编码：
  2930909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P264,P270,P301+P312,P330,P403,P501
• 危险性描述：
  H302
• 储存条件：
  请将容器密封，并将其存放在紧密封装的容器中，储存在阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chlorothiobenzamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H317: May cause an allergic skin reaction
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chlorothiobenzamide
CAS number: 2548-79-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6ClNS
Molecular weight: 171.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯苯硫酰胺 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 2-(3-chlorophenyl)-1,3-thiazole-4-carbohydrazide
  参考文献：
  名称：

  新恶二唑和噻唑类似物的合成，晶体结构，抗HIV和抗增殖活性

  摘要：

  合成了一系列2-金刚烷基-5-芳基噻唑基-1,3,4-恶二唑7a – x以及噻唑13和14。化合物7a中-升，13，和14在体外用的鉴定新的铅在MT-4细胞的化合物对人免疫缺陷病毒1型和人免疫缺陷病毒2型活性的活性的目的进行了测试。还测试了标题化合物对革兰氏阳性和革兰氏阴性细菌（金黄色葡萄球菌，沙门氏菌），各种分枝杆菌菌株（Fort分支杆菌和耻垢分枝杆菌（Mycobacterium smegmatis），酵母（白色念珠菌）和霉菌（Aspergillus fumigatus）。除了化合物13和14表现出抗人免疫缺陷病毒1活性（EC 50值为1.79和2.39μM，选择性指数分别为18和4）外，所有化合物均未显示出抗病毒或抗微生物活性。另一方面，化合物7a和7j对人CD4 +淋巴细胞（MT-4）显示出明显的细胞毒性。因此，评估了7a和7j对两种表现出IC的实体肿瘤衍生细胞系的抗增殖活性针对Hep-G2细胞系的50个值分别为8

  DOI：

  10.1007/s00044-016-1669-9
• 作为产物：
  描述：

  3-氯苯腈 在 diphosphorus pentasulfide 、 乙醇 作用下， 反应 4.0h， 以88%的产率得到3-氯苯硫酰胺
  参考文献：
  名称：

  五硫化磷：一种用于从腈制备硫代酰胺的温和多功能试剂

  摘要：

  开发了一种简单、高效、新的方法，用于从腈中合成硫代酰胺。多种芳香族和脂肪族腈在五硫化二磷存在下的反应以高产率提供相应的硫代酰胺。该方法简便、快速、收率高，可用于从腈中合成硫代酰胺。

  DOI：

  10.1055/s-2005-918507

文献信息

• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• A Thiophosphoryl Chloride Assisted Transformation of Arylaldoximes to Thioamides
  作者：Uma Pathak、Lokesh Pandey、Sweta Mathur、M. Suryanarayana

  DOI：10.1055/s-0031-1289994

  日期：2012.2

  Primary benzothioamides were accessed from benzaldoximes (benzaldehyde oximes) via benzonitriles in a sequential tandem approach utilizing thiophosphoryl chloride as a dehydrating and thionating agent. primary thioamides - oximes - thiophosphoryl chloride - nitriles

  使用硫代磷酰氯作为脱水剂和去硫剂，通过苯甲腈通过苯甲腈从苯甲醛肟（苯甲醛肟）中获得伯苯硫酰胺。 伯硫代酰胺-肟-硫代磷酰氯-腈
• MEDICINAL COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1402900A1

  公开（公告）日：2004-03-31

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制破骨细胞活化的药剂，以及一种包含p38 MAP激酶抑制剂和/或TNF-α产生抑制剂的破骨细胞形成抑制剂。
• CONCOMITANT DRUGS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1354603A1

  公开（公告）日：2003-10-22

  The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

  本发明涉及一种含有一种或多种p38 MAP激酶抑制剂和/或TNF-α产生抑制剂以及从（1）非甾体抗炎药、（2）疾病修饰性抗风湿药、（3）抗细胞因子药物、（4）免疫调节剂、（5）类固醇和（6）c-Jun N末端激酶抑制剂中选择的一种或多种药物的药物制剂。这种组合药剂可用作预防或治疗风湿病、关节炎等疾病以及其他疾病的药物。
• Synthesis and Antimicrobial Screening of 2-Aryl-5-((2-arylthiazol-4-yl)methyl)-1,3,4-oxadiazole Derivatives
  作者：Pravin C. Mhaske、Shivaji H. Shelke、Manish Bhoye、Vivek D. Bobade

  DOI：10.1002/jhet.2747

  日期：2017.3

  A new series of 2‐aryl‐5‐((2‐arylthiazol‐4‐yl)methyl)‐1,3,4‐oxadiazole derivatives was synthesized by condensation of 2‐(2‐substituted thiazol‐4‐yl)acetohydrazide with aryl aldehydes followed by oxidative cyclocondensation using iodobenzene diacetate. The structure of synthesized compounds was characterized by IR, NMR, and mass analysis. All the newly synthesized compounds were evaluated for their

  通过2-（2-取代的噻唑-4-基）乙酰肼与2-肼的缩合反应合成了一系列新的2-芳基-5-（（（2-芳基噻唑-4-基）甲基）-1,3,4-恶二唑衍生物芳基醛，然后使用碘代苯二乙酸酯进行氧化环缩合。合成的化合物的结构通过IR，NMR和质量分析表征。评价所有新合成的化合物的体外抗菌活性。一些化合物显示出中等的抗菌活性。